Transcription Factor Regulation in Cancer Pathways

Transcription factors act as master regulators of gene expression by binding specific DNA sequences and recruiting co-regulatory complexes that modulate chromatin structure and transcriptional output. In cancer, aberrant transcription factor activity can arise from genetic mutations, altered expression levels or dysregulated post-translational modifications. Such perturbations often reprogramme cellular programmes governing proliferation, apoptosis, differentiation and migration. Core signalling cascades, including Wnt/β-catenin, MAPK and PI3K/AKT, intersect extensively with transcription factors to reinforce oncogenic transcriptional networks. Moreover, transcription factors cooperate with epigenetic modifiers and non-coding RNAs to establish permissive or repressive chromatin domains at target loci. This intricate interplay underpins processes such as epithelial–mesenchymal transition, maintenance of cancer stem cell states and evasion of immune surveillance. Understanding the multifaceted regulation of transcription factors in malignancies has yielded promising targets for therapeutic intervention, from small-molecule inhibitors of DNA-binding domains to degraders of co-activator interfaces, highlighting the global significance of this research for precision oncology.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Transcription Factor Regulation in Cancer Pathways publication trend

The graph below shows the total number of articles in transcription factor regulation in cancer pathways across all publications each year (not limited to Nature Index journals).

Technical terms

Transcription factor: A protein that recognises specific DNA motifs to regulate gene transcription by recruiting RNA polymerase and co-regulators.

Epigenetic modification: A heritable chemical change to DNA or histones, such as methylation or acetylation, that influences chromatin accessibility and gene expression without altering the nucleotide sequence.

Chromatin immunoprecipitation: An experimental technique used to map the binding sites of DNA-associated proteins in cells by crosslinking, immunoprecipitating and sequencing bound DNA fragments.

Epithelial–mesenchymal transition (EMT): A cellular programme in which epithelial cells acquire mesenchymal traits, enhancing motility and invasiveness, often driven by transcription factors such as SNAIL and ZEB.

Non-coding RNA: RNA molecules, including microRNAs and long non-coding RNAs, that do not code for proteins but regulate gene expression at transcriptional or post-transcriptional levels.

References

1. Crucial role of the transcription factors family activator protein 2 in cancer: current clue and views. Journal of Translational Medicine (2023).
2. Differential Expression of AP-2 Transcription Factors Family in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma—A Bioinformatics Study. Cells (2023).
3. Activator Protein 2α Associates with Adenomatous Polyposis Coli/β-Catenin and Inhibits β-Catenin/T-cell Factor Transcriptional Activity in Colorectal Cancer Cells*. Journal of Biological Chemistry (2004).
4. Tumor Suppressor Activity of AP2α Mediated through a Direct Interaction with p53*. Journal of Biological Chemistry (2002).